PTAFR and neoplasm: decrease in the maximum inhibitory concentration (IC50) of gemcitabine in tumor cells of the BxPC-3, CAPAN1, PANC1 and MIA PaCa-2 linesin combination with gemcitabine: inhibiting cell proliferation; inhibiting tumor growth; increasing cell apoptosis; no effect when gemcitabine and extract are used separatelysuppression of the effect of gemcitabine in the following areas: increase in NF-kB activity and PAFR and phosphorylated NF-kB/p65 expressionsuppression of PAFR expressionno effect on the IC50 of gemcitabine in IκBα-SR